Veradermics Stock Jumps 9% on Promising Mid-Stage Hair Loss Trial Data

Shares of Veradermics, Incorporated (NYSE: MANE) climbed 9% in Wednesday trading after the biotechnology company released encouraging results from a mid-stage clinical trial of its experimental oral treatment for female pattern hair loss.

Trial Shows Significant Efficacy

Veradermics reported positive data from its Study 207, an open-label Phase 2 trial evaluating VDPHL01, an extended-release oral minoxidil formulation. The study focused on female participants with mild-to-moderate pattern hair loss.

According to the company's announcement, the trial met its key endpoints, demonstrating notable hair growth at the six-month mark. Key findings include:

• A mean increase in non-vellus target area hair count of 22.7 hairs/cm² for patients on a once-daily dose.
• A mean increase of 23.3 hairs/cm² for those on a twice-daily dose.
• A high rate of patient-reported improvement, with 88.9% of the once-daily group and 90.0% of the twice-daily group reporting their condition as "improved" or "much improved."

Ad

Favorable Safety and Next Steps

The company stated that VDPHL01 exhibited a favorable safety profile throughout the trial. No treatment-related serious adverse events were reported, and importantly, no cardiac-related adverse events of special interest were observed through Month 6.

These positive results support the drug's potential to become the first FDA-approved oral treatment for female pattern hair loss. Veradermics is also advancing a parallel program for male pattern hair loss, with topline results from a Phase 3 study (Study 304) anticipated in the second half of 2026. For the female indication, the company expects topline results from its pivotal Phase 2/3 trial (Study 306) in the first half of 2027.